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Abstract: AIMS OF THE STUDY Cystic fibrosis is the most common genetic disorder in Caucasians. The
combination of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector lumacaftor
/ potentiator ivacaftor (LUM/IVA) has been shown to increase forced expiratory volume in 1 second
(FEV1) moderately, but predominantly reduce acute exacerbation rate (AER) in Phe508del homozygous
cystic fibrosis patients; however, patients with FEV1 <40% predicted were excluded from studies. We
used LUM/IVA on a “compassionate use” basis in cystic fibrosis patients with end-stage pulmonary
disease. Our aim was to evaluate if this patient cohort tolerates LUM/IVA treatment and if there is
clinical stabilisation. Lung transplantation (LTX) is the ultimate treatment option for these patients
despite maximal therapy. If LTX candidates stabilise clinically, conditions for LTX, when it is indicated,
improve. This is particularly important in countries such as Switzerland with a low organ donation rate
and long waiting times for suitable donor organs. METHODS We included all patients from the Adult
Cystic Fibrosis Centre at the University Hospital Zurich with Phe508del homozygous genotype and a
predicted FEV1 <40% or being evaluated or already listed for LTX. Clinical outcome data comprised
AER, 6-minute walking distance (6-MWD), FEV1, forced vital capacity (FVC), mid-expiratory flow
(MEF 25–75%), sweat chloride, body mass index (BMI) and quality of life. Respiratory-related adverse
events (RAEs) were recorded. LUM/IVA treatment was initiated at a low dose and the dose increased
stepwise. RESULTS Twenty patients were on trial with LUM/IVA; at the cut-off date, 6-month follow-up
was complete for 10 patients. RAEs were severe and occurred early. The dropout rate due to RAE or lack
of clinical success was 20%. Median AER decreased from 2.5 in the 6 months pre-treatment to 1 during
the observation period. FEV1 increased from 32 to 34.5% predicted, p = 0.292. The 6-MWD increased
by a median 33 m (p = 0.6086). Sweat chloride decreased significantly by a median of 25 mmol/l (p =
0.0003). Median BMI increased from 19 to 19.9 kg/m2 (p = 0.1488). At the cut-off, three previously
listed patients were paused on the transplant waiting list. CONCLUSION Phe508del homozygous cystic
fibrosis patients with end-stage pulmonary disease tolerated LUM/IVA, although RAEs occurred early
and were severe. This positive finding was probably due to the stepwise dose increases. There was clinical
benefit mainly from reduction in AER and stabilisation of lung function. We propose that all suitable
Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease should have a trial of
LUM/IVA treatment in experienced centres. Keywords: cystic fibrosis, CFTR-modulator, end-stage
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Summary
AIMS OF THE STUDY: Cystic fibrosis is the most common
genetic disorder in Caucasians. The combination of the
cystic fibrosis transmembrane conductance regulator
(CFTR) corrector lumacaftor / potentiator ivacaftor (LUM/
IVA) has been shown to increase forced expiratory volume
in 1 second (FEV1) moderately, but predominantly reduce
acute exacerbation rate (AER) in Phe508del homozygous
cystic fibrosis patients; however, patients with FEV1 <40%
predicted were excluded from studies. We used LUM/IVA
on a “compassionate use” basis in cystic fibrosis patients
with end-stage pulmonary disease. Our aim was to evalu-
ate if this patient cohort tolerates LUM/IVA treatment and
if there is clinical stabilisation. Lung transplantation (LTX)
is the ultimate treatment option for these patients despite
maximal therapy. If LTX candidates stabilise clinically, con-
ditions for LTX, when it is indicated, improve. This is par-
ticularly important in countries such as Switzerland with a
low organ donation rate and long waiting times for suitable
donor organs.
METHODS: We included all patients from the Adult Cystic
Fibrosis Centre at the University Hospital Zurich with
Phe508del homozygous genotype and a predicted FEV1
<40% or being evaluated or already listed for LTX. Clinical
outcome data comprised AER, 6-minute walking distance
(6-MWD), FEV1, forced vital capacity (FVC), mid-expirato-
ry flow (MEF 25–75%), sweat chloride, body mass index
(BMI) and quality of life. Respiratory-related adverse
events (RAEs) were recorded. LUM/IVA treatment was ini-
tiated at a low dose and the dose increased stepwise.
RESULTS: Twenty patients were on trial with LUM/IVA;
at the cut-off date, 6-month follow-up was complete for
10 patients. RAEs were severe and occurred early. The
dropout rate due to RAE or lack of clinical success was
20%. Median AER decreased from 2.5 in the 6 months
pre-treatment to 1 during the observation period. FEV1
increased from 32 to 34.5% predicted, p = 0.292. The
6-MWD increased by a median 33 m (p = 0.6086). Sweat
chloride decreased significantly by a median of 25 mmol/l
(p = 0.0003). Median BMI increased from 19 to 19.9 kg/m2
(p = 0.1488). At the cut-off, three previously listed patients
were paused on the transplant waiting list.
CONCLUSION: Phe508del homozygous cystic fibrosis
patients with end-stage pulmonary disease tolerated LUM/
IVA, although RAEs occurred early and were severe. This
positive finding was probably due to the stepwise dose in-
creases. There was clinical benefit mainly from reduction
in AER and stabilisation of lung function. We propose that
all suitable Phe508del homozygous cystic fibrosis patients
with end-stage pulmonary disease should have a trial of
LUM/IVA treatment in experienced centres.
Key words: cystic fibrosis, CFTR-modulator, end-stage
pulmonary disease
Introduction
Cystic fibrosis, the most common genetic disorder in Cau-
casians, is caused by autosomal recessive mutations of
the cystic fibrosis transmembrane conductance regulator
(CFTR), an anion channel expressed on the apical surfaces
of epithelial cells in airways, pancreatic ducts and other tis-
sues. In Europe, 1 in 2000–3000 newborns are affected by
cystic fibrosis [1, 2]. CFTR mutations can be categorised
into seven classes on the basis of the aberrant CFTR syn-
thesis or function [3].
As there is currently no cure for cystic fibrosis, progressive
lung disease is the leading cause of death. New treatments
targeting the CFTR protein in patients with gating muta-
tions are promising [4]. Recently, a combination of the
CFTR corrector lumacaftor (LUM) and CFTR potentiator
ivacaftor (IVA) has been shown to moderately increase
the primary study endpoint of forced expiratory volume in
1 second (FEV1), but predominantly to reduce the acute
exacerbation rate in Phe508del homozygous patients with
cystic fibrosis [5]; however, patients with a FEV1 <40%
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predicted were excluded from this and other CFTR modu-
lator trials [4, 5].
LUM/IVA was approved by the US Food and Drug Ad-
ministration (FDA) in July 2015 and by the European
Medicines Agency (EMA) in November 2015. In Switzer-
land, the drug was licensed in September 2016; however,
reimbursement by health insurers is not yet compulsory.
As this therapy offers a new opportunity in Phe508del
homozygous patients with end-stage cystic fibrosis pul-
monary disease, we decided to use LUM/IVA on a “com-
passionate use” basis. In every individual case we seek re-
imbursement from health insurance.
Our aim was to evaluate if this patient cohort tolerates
LUM/IVA treatment. Further, we hypothesised that LUM/
IVA might lead to clinical stabilisation, even in patients
with end-stage cystic fibrosis pulmonary disease.
Material and methods
This was a single-centre prospective observational study
in which LUM/IVA (Orkambi®, Vertex Pharmaceuticals,
MA, USA) was taken orally by Phe508del homozygous
patients with end-stage cystic fibrosis pulmonary disease.
The study was conducted from January 2016 to January
2017. All patients were cared for at our Adult Cystic Fi-
brosis and Transplant Centre at the University Hospital
Zurich. At the time, we were caring for 102 patients with
cystic fibrosis of whom 47 were Phe508del homozygous.
Data for the 6 months before LUM/IVA initiation were
collected prospectively. Basic patient information was ob-
tained from the electronic patient files at the University
Hospital Zurich. The study was approved by the local
Ethics Committee (EK 2016-01494).
We included all adult patients with cystic fibrosis from
our centre with Phe508del homozygous genotype and who
had a FEV1 <40% predicted, or were under evaluation or
already listed for lung transplantation in accordance with
international guidelines [6]. No patient refused a trial of
LUM/IVA. All patients were excluded from participation
in ongoing trials of CFTR modulators in Switzerland be-
cause of their FEV1 of <40%.
Exclusion criteria were as follows: history of solid organ or
haematological transplantation, pregnancy or breast-feed-
ing, alanine aminotransferase (ALT) or aspartate amino-
transferase (AST) >5 × upper limit of reference range (UL-
RR); or ALT or AST >3 × ULRR and bilirubin >2 ×
ULRR.
As there is limited information about the tolerability of
LUM/IVA in cystic fibrosis patients with end-stage pul-
monary disease, we decided to implement the following
protocol. Patients received the first tablet in the outpatient
clinic with a 3-hour monitoring period. Afterwards, the
drug dose was increased stepwise until the maintenance
dose was reached (two tablets twice daily: LUM 400 mg
every 12 h and IVA 250 mg every 12 h). Our cystic fibrosis
nurse followed patients up by phone every third day, as-
sessing patients’ overall wellbeing and the drug tolerabil-
ity. If the patient tolerated LUM/IVA, the daily dose was
increased by one tablet. In the case of adverse events, the
dose was reduced by one tablet. In general, when there was
an amelioration of symptoms due to adverse events after a
dose reduction of one tablet, we increased the dose again
by one tablet after a stabilisation period of 2 weeks. If ad-
verse events persisted despite dose reduction by one tablet,
we further reduced the dose by one tablet. Patients were
evaluated every 4 weeks in the outpatient clinic.
Outcome data comprised acute exacerbation rate according
to the modified Fuchs-criteria [7]. The modality of treat-
ment was based on clinical judgement of the treating
physician (ambulatory vs home treatment). Further out-
come parameters were: 6-minute walking distance
(6-MWD), FEV1, forced vital capacity (FVC), mid-expira-
tory flow (MEF 25–75%), sweat chloride, body mass in-
dex (BMI) and quality of life. Lung function tests were ob-
tained accordingly [8]. Quality of life was assessed using a
standard questionnaire (The revised German Cystic Fibro-
sis Questionnaire [CFQ-R]); from the total of 12 domains,
we focused on the two most relevant (“physical” and “res-
piratory”) according to the patients’ feedback [9]. Sweat
chloride was measured between 1 week before starting
with LUM/IVA and the end of the 6 months of follow-up
at University Children’s Hospital Zurich, a Swiss nation-
al reference centre, with use of the macroduct collection
system. The number of acute exacerbations during the 6
months before treatment were recorded. Respiratory-re-
lated adverse events (dyspnoea, chest-tightness, increased
sputum production, pulmonary exacerbation) were record-
ed as described by Popowicz et al. [10].
Detailed drug information was given to the patient by the
physician. All patients agreed to participate in a CFTR
modulator trial. Written informed consent was collected
from all patients on the general informed consent form
(“Generalkonsent”, USZ). In Switzerland, criteria for treat-
ment success of CFTR modulator therapy exist only for
IVA. Therefore, we defined treatment success in accor-
dance with Wainwright et al. [5] as follows: reduction of
the acute exacerbation rate by at least 30% or absolute im-
provement in FEV1 or FVC by 3% or improvement in BMI
by 1%. If patients on the transplant waiting list, fulfilled a
minimum of two of the given criteria, this resulted in in-
activation on the waiting list. In the case of treatment suc-
cess, therapy continued.
Statistics
Descriptive statistics were used for this retrospectively col-
lected data. Because of the small sample size and not nor-
mally distributed data, median values of the physiological
variables were computed. Paired comparisons were per-
formed by t-tests. An exact sign test was used to compare
the differences in the scores of the CFQ-R domains “phys-
ical” and “respiratory”. A p-value <0.05 was considered
statistically significant.
Results
At the cut-off date, 20 patients were on a trial of LUM/
IVA. Here, we present 10 patients who had already com-
pleted 6 months of follow-up. Respiratory adverse event
data during the first month were recorded for all 20 pa-
tients. Complete data on 6-MWD and sweat chloride were
available for all but one patient, and completed CFQ-R re-
sults for all but two patients.
Baseline characteristics (n = 10) are as follows. All patients
were male, all had pancreatic insufficiency, six patients
had cystic fibrosis-related diabetes mellitus and seven pa-
tients had chronic Pseudomonas aeruginosa pulmonary in-
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fection; no patient had Burkholderia cepacia complex. Pa-
tients were suffering from severe airway obstruction with a
median FEV1 of 1.31 L (32% predicted, 18–44%), one had
a FEV1 <20% predicted, four had a FEV1 between 21 and
30% predicted and four had a FEV1 between 31and 40%
predicted. For the 20 patients in the respiratory adverse
event analysis, median predicted FEV1 was 1.23 L (29.5%
predicted, 16–49%), two had a FEV1 <20% predicted, nine
had a FEV1 between 21 and 30% predicted and seven had
a FEV1 between 31and 40% predicted. Three patients were
on a waiting list for lung transplantation, and one patient
was being evaluated for lung transplantation.
Most patients suffered from respiratory adverse events dur-
ing treatment initiation, starting just a few hours after the
first intake, and these were present in 95% after 24 hours,
mainly chest tightness and increased sputum production
(table 1). After 1 month, events persisted in only 35%
of patients. All but three patients were at full dose by 1
month. One patient had to stop LUM/IVA indefinitely 24
hours after the first tablet intake owing to severe chest
tightness. Therapy was stopped after 2 months in one pa-
tient and after 6 months in two patients because of lack of
clinical success. Of these three patients, two subsequently
had a successful lung transplant.
Median acute exacerbation rate decreased from 2.5 (range
0–6) before treatment to 1 (0–4) at 6 months (p = 0.0718).
There was an increase in median FEV1 from 32% predicted
(18–44%) to 34.5% (21–46%) (p = 0.292) and in median
FVC from 56% predicted (21–60%) to 59% (40–71%) (p =
0.2179). Median MEF 25–75% remained unchanged (p =
0.784). An increase in 6-MWD of median 33 m was noted
(n = 9; p = 0.6086). Sweat chloride decreased significantly
by a median 25 mmol/l (n = 9; p = 0.0003) (fig. 1). Me-
dian BMI increased from 19 kg/m2 (17–24.9) to 19.9 kg/
m2 (16.2–25.3) (p = 0.1488). The score of the CFQ-R do-
main “physical” elicited a statistically significant median
increase at month 6 compared with baseline (p = 0.031),
whereas the score of the “respiratory” domain did not sig-
nificantly change (n = 8; p = 0.22). Outcome parameters
are shown in table 2. As a result of clinical improvement,
three patients are currently paused on the transplant wait-
ing list.
Discussion
Our study showed that Phe508del homozygous patients,
even with end-stage cystic fibrosis pulmonary disease, tol-
erated LUM/IVA, although respiratory adverse events
were severe. The low dropout rate was probably due to our
protocol, with a low starting dose of LUM/IVA and careful
dose increases thereafter. In our patients (who were not el-
igible for phase III clinical trials), the clinical benefit was
mainly from a reduction in acute exacerbation rate and sta-
bilisation of lung function on treatment with LUM/IVA.
Table 1: Respiratory-related adverse events from patients (n = 20), at 3 hours, 24 hours and 1 month, according to Popowicz et al [10].
3 hours 24 hours 1 month
Dyspnoea, n (%) 0 1 (5%) 1 (5%)
Chest tightness, n (%) 1 (5%) 10 (50%) 1 (5%)
Increased sputum production, n (%) 1 (5%) 8 (40%) 3 (15%)
Pulmonary exacerbation. n (%) 0 0 2 (10%)
n = number of participants.
Figure 1: Change in sweat chloride from pre-treatment to 6 months of treatment.
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In the combined TRAFFIC and TRANSPORT studies, in-
clusion criteria were a FEV1 at time of screening of
40–90% predicted [5]. Of 1108 patients included in the ef-
ficacy analysis, 81 had a FEV1 that decreased to <40% pre-
dicted between baseline and screening with a mean FEV1
of 37% predicted. A subgroup analysis of these patients
showed an absolute increase in FEV1 of 3.3 to 3.7% pre-
dicted [11]. In contrast, our patients suffered from more
severe cystic fibrosis pulmonary disease, with a median
FEV1 of 32% predicted. In our cohort, median FEV1 in-
creased by 2.5% and FVC by 3% predicted on LUM/IVA.
Although this change was not statistically significant and
the sample size was small, it is an important finding that
lung function at least stabilised in this patient cohort.
Besides the increase in change of 6-MWD (median 33
m), weight gain in this underweight cystic fibrosis popu-
lation with end-stage pulmonary disease was another re-
markable finding. In our view, the most important clinical
benefit was the reduction in acute exacerbation rate, main-
ly leading to clinical stabilisation or even improvement.
The health-related quality of life domain “physical” sig-
nificantly increased, confirming our clinical observation
that most patients on LUM/IVA have improved wellbeing
and mobility. On the basis of the defined treatment success
criteria, three patients listed for lung transplantation were
paused on the waiting list.
At 6 months’ follow-up, sweat chloride decreased, demon-
strating an effect on chloride channel function. Interesting-
ly, the decrease in change of sweat chloride did not corre-
late with an improvement in other biomarkers investigated
in our patients. Boyle et al. showed that there was no cor-
responding improvement in FEV1 and sweat chloride in
Phe508del homozygous patients with cystic fibrosis treat-
ed with LUM/IVA. The authors concluded that there is a
differential effect on CFTR function in the lung and sweat
glands [12]. Recently published combined analysis of data
from eight clinical trials evaluating the effect of IVA on
sweat chloride showed that sweat chloride level changes
appear to be a predictive pharmacodynamic biomarker of
lung function changes on a population basis, but are un-
suitable for the prediction of treatment benefits for indi-
viduals [13]. However, because of the small sample size,
our results are underpowered to answer this question and,
of course, the between-test variability must be considered
[14].
Our patients suffered from intense and early respiratory-re-
lated adverse events. The subgroup analysis of the TRAF-
FIC and TRANSPORT studies also showed that the in-
cidence of respiratory adverse events was greater in the
LUM/IVA group than in the placebo group. Such events
occurred earlier in the patients with FEV1 <40% predicted
[11]. The same has been shown in the real-world studies
evaluating the effect of LUM/IVA therapy in Phe508del
homozygous cystic fibrosis patients with end-stage pul-
monary disease from Popowitz et al. and Hubert et al., in
which all but one patient were on full-dose therapy [10,
15]. In the most recent prospective US multicentre study
by Taylor-Cousar et al., the overall incidence of respiratory
adverse events in the 24 weeks of the study was 65%, with
an early onset; 39% of the patients initially received half of
the recommended dose for 1 to 2 weeks, followed by dose
escalation [16]. In our patient cohort, the incidence of res-
piratory adverse events was 95% after 24 hours, but down
to 35% at 1 month. However, caution is needed when com-
paring these different studies because of heterogeneity in
the assessment and reporting of respiratory adverse events.
Clinicians should be aware of this and be in close contact
with patients during treatment initiation. If respiratory
symptoms increased after stepwise dose augmentation, pa-
tients were advised to reduce their dose. We observed that
administration of short-acting and/or long-acting bron-
chodilators ameliorated chest tightness. This effect has also
been shown in a study with healthy subjects [17]. Recent
studies had dropout rates of 30% (24% due to adverse res-
piratory events, n = 53) starting with the full (recommend-
ed) dose, 32% (n = 19) and 25% (n = 12), respectively [10,
15, 18]. In the study reported by Taylor-Cousar et al. (in
which 39% of patients started with half of the recommend-
ed dose), there was a dropout rate of 17% (n = 46) due
to any adverse events, but 24% of patients did not com-
plete the 24 weeks of treatment. Taking all patients from
our cohort (n = 20), including 10 patients with a complete 6
months of follow-up, we had a dropout rate of 20%, main-
ly due to lack of clinical success; only one patient stopped
treatment because respiratory adverse events. We believe
that our stepwise approach helped to ameliorate and/or im-
prove tolerance of these adverse events. However, patients
such as ours should be carefully selected before treatment
initiation, as they often have little reserve. We propose that
these patients should be started on LUM/IVA treatment on-
ly in experienced cystic fibrosis centres.
Our study had limitations. It was a single-centre, investiga-
tor-driven study with a small sample size and no matched
controls. By chance, the 6-month follow-up only included
males, one female was included in the adverse event analy-
sis of the total cohort. This has to be considered, as a gen-
der difference exists among cystic fibrosis patients, and fe-
males might potentially suffer from more severe adverse
events. We had no change of concomitant medication dur-
ing the study. Adherence to treatment is difficult to assess.
Table 2: Outcome parameters at baseline and after 6 months.
Baseline 6 months p-value
AER (n = 10) 2.5 (0–5) 1 (0–4) 0.072
FEV1 (% predicted) (n = 10) 32 (18–44) 34.5 (2146) 0.292
FVC (% predicted) (n = 10) 55 (21–50) 59 (40–71) 0.218
Sweat chloride (mmo1/1) (n = 9) 102 73 0.0103
BMI (kg/m2) (n = 10) 19 (17–24.9) 19.9 (16.2–25.3) 0.149
CFQ-R score (n = 8)
Domain “physical” 59 (37–100) 90 (63–100) 0.031
Domain “respiratory” 53 (33–100) 75 (50–100) 0.220
n = number of participants AER = acute exacerbation rate; BMI = body mass index; CFQ-R = the revised German Cystic Fibrosis Questionnaire; FVC = forced vital capacity;
FEV1 = forced expiratory volume in 1 second
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However, we found no clear evidence of poor adherence.
Regarding the high cost of the CFTR-modulator therapy,
we were unfortunately unable to compare the cost of lung
transplantation and post-transplant care vs LUM/IVA treat-
ment.
Lung transplantation is the ultimate treatment option for
end-stage cystic fibrosis pulmonary disease despite maxi-
mal therapy [6]. New treatments including CFTR-modula-
tors, ought to be tested [19]. If lung transplant candidates
stabilise clinically, conditions for transplantation, when fi-
nally required, improve. This is particularly important in
countries such as Switzerland with a low organ donation
rate and long waiting times for suitable donor organs.
To conclude, our results show that in Phe508del homozy-
gous cystic fibrosis patients with end-stage lung disease,
LUM/IVA is tolerated although respiratory adverse events
are sever and occur early. We propose that all suitable cys-
tic fibrosis patients with end-stage pulmonary disease re-
ceive LUM/IVA treatment, under a protocol with stepwise
increases of the dose.
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